PDCD1 and melanoma: For example, in trials of PD-1 inhibitors for melanoma, the KEYNOTE-001 trial (pembrolizumab) (59) and the CheckMate 067 trial (nivolumab) (5) both reported benefit in patients who were either positive and negative for PD-L1 in two different IHC tests.